Skip to main content
NewslettersWatchlist

Cerevel Therapeutics Hldg Inc(CERE-Q)
NASDAQ

Today's Change
Real-Time Last Update Last Sale Cboe BZX Real-Time
Day Low41.70
Day High42.21
Open:41.88
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Realtime quote and/or trade prices are not sourced from all markets.
Select a category then submit the form to load news
Motley Fool
Is AbbVie Stock a Buy Now?
Motley Fool
Is AbbVie Stock a Buy Now?
Motley Fool
4 Top Dividend Stocks Yielding More Than 4% to Buy Hand-Over-Fist This December
Motley Fool
AbbVie Just Announced 2 Big Acquisitions: Is This Dividend King a No-Brainer Buy Right Now?
Motley Fool
AbbVie's on an Acquisition Binge. Could Your Favorite Biotech Stock Be Next?
PR Newswire
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cerevel Therapeutics Holdings, Inc. - CERE
PR Newswire
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cerevel Therapeutics Holdings, Inc. - CERE
PR Newswire
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cerevel Therapeutics Holdings, Inc. - CERE
Motley Fool
Why Shares of Cerevel Therapeutics Are Dropping Wednesday
PR Newswire
Quantiphi Collaborates with Cerevel Therapeutics to Harness the Power of Google Cloud's AI in Clinical Workflow Management
Globe Newswire
Cerevel Therapeutics Announces Proposed Public Offering of Common Stock
Globe Newswire
Cerevel Therapeutics Announces Proposed Private Offering of Convertible Senior Notes
Globe Newswire
Cerevel Therapeutics Reports Second Quarter 2022 Financial Results and Business Updates
Globe Newswire
Cerevel Therapeutics to Report Second Quarter 2022 Financial Results and Pipeline Update on Monday, August 1, 2022
Globe Newswire
Cerevel Therapeutics Announces Updates to its Board of Directors
Globe Newswire
Cerevel Therapeutics to Present at the Jefferies Healthcare Conference
Globe Newswire
Cerevel Therapeutics Reports First Quarter 2022 Financial Results and Business Updates
Globe Newswire
Cerevel Therapeutics to Report First Quarter 2022 Financial Results and Pipeline Update on Tuesday, May 10, 2022
Globe Newswire
Cerevel Therapeutics Announces Upcoming Presentations at AAN 2022
Globe Newswire
Cerevel Therapeutics to Present at the Stifel 4th Annual CNS Day Event
Globe Newswire
Cerevel Therapeutics Provides Update on Pipeline Progress along with Fourth Quarter and Full Year 2021 Financial Results
Globe Newswire
Cerevel Therapeutics to Report Fourth Quarter 2021 Financial Results and Pipeline Update on Tuesday, March 1, 2022
Globe Newswire
Cerevel Therapeutics Announces Positive Topline Results for Darigabat in Phase 1 Clinical Trial in Acute Anxiety
Globe Newswire
Cerevel Therapeutics to Present at 40th Annual JP Morgan Healthcare Conference: Additional Details of Phase 2 Program for Emraclidine (CVL-231) in Schizophrenia to be Presented
Globe Newswire
Cerevel to Present at the 40th Annual J.P. Morgan Healthcare Conference
Globe Newswire
Cerevel Therapeutics and Herophilus Announce Collaboration to Evaluate Novel Neuroimmune Modulating Therapeutic Strategies for Schizophrenia
Globe Newswire
Cerevel Therapeutics Reports Third Quarter 2021 Financial Results and Pipeline Updates
Globe Newswire
Cerevel Therapeutics to Participate at Upcoming Virtual Investor Conferences
Globe Newswire
Cerevel Therapeutics to Report Third Quarter 2021 Financial Results on Wednesday, November 10, 2021
Globe NewsWire
Cerevel Therapeutics Announces Departure of CFO Kathy Yi
Globe NewsWire
Cerevel Therapeutics to Host Virtual R&D Event on October 7
Globe NewsWire
Cerevel Therapeutics to Present at Upcoming Virtual Investor Conferences

Profile

Cerevel Therapeutics Inc. treats neuroscience diseases. The company's diversified pipeline comprising clinical-stage investigational therapies and several preclinical compounds to treat neuroscience diseases, including schizophrenia, epilepsy, Parkinson's disease and substance use disorder. Cerevel Therapeutics Inc., formerly known as Acquisition Corp II, is headquartered in Boston.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2024.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

Copyright © 2024 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.